Literature DB >> 12568300

Recovery of normal hematopoiesis after severe bone marrow aplasia induced by interferon-alpha in a patient with chronic myelogenous leukemia.

Asahi Hishida1, Kazuhito Yamamoto, Chiaki Kato, Toshiya Yokozawa, Nobuhiko Emi, Mitsune Tanimoto, Hidehiko Saito.   

Abstract

We describe an interesting case of a patient with chronic myelogenous leukemia (CML) who developed sustained severe bone marrow aplasia after 2 years and 11 months of interferon-alpha (IFN-alpha) therapy but demonstrated recovery of normal hematopoiesis when treated with immunosuppressive therapy with granulocyte-colony stimulating factor (G-CSF). Administration of G-CSF resulted in a partial recovery of hematopoiesis, and after starting immunosuppressive therapy, the patient was no longer dependent on blood transfusions. Moreover, her bone marrow had no Philadelphia chromosome-positive clones. According to the results of the present case, bone marrow recovery can be achieved with immunosuppressive therapy and a fatal outcome avoided, even in CML patients suffering from sustained bone marrow aplasia during IFN-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12568300     DOI: 10.1007/BF02982603

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

1.  Persisting bone marrow aplasia following interferon-alpha combined with ara-C for chronic myelogenous leukemia.

Authors:  M Fiegl; A Chott; H L Seewann; K Lechner; H Gisslinger
Journal:  Leuk Lymphoma       Date:  1999-06

Review 2.  Bone marrow cytogenetic abnormalities of aplastic anemia.

Authors:  Y K Keung; M J Pettenati; J M Cruz; B L Powell; R D Woodruff; D H Buss
Journal:  Am J Hematol       Date:  2001-03       Impact factor: 10.047

3.  A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia.

Authors:  C Bilhou-Nabera; G Marit; I Devianne; F Viard; S Salzes; M Montastruc; M Renoux; A Broustet; J Reiffers; P Bernard
Journal:  Genes Chromosomes Cancer       Date:  1993-04       Impact factor: 5.006

4.  Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia.

Authors:  T Ariyama; J Inazawa; Y Uemura; N Kakazu; T Maekawa; F Urase; K Irimajiri; A Horiuchi; Y Nakamura; T Abe
Journal:  Cancer Genet Cytogenet       Date:  1995-05

5.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.

Authors:  M Talpaz; H Kantarjian; R Kurzrock; J M Trujillo; J U Gutterman
Journal:  Ann Intern Med       Date:  1991-04-01       Impact factor: 25.391

6.  Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.

Authors:  A Ohara; S Kojima; N Hamajima; M Tsuchida; S Imashuku; S Ohta; H Sasaki; J Okamura; K Sugita; H Kigasawa; Y Kiriyama; J Akatsuka; I Tsukimoto
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

7.  Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K B McCredie; M J Keating; J Trujillo; J Gutterman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

8.  Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin.

Authors:  K F Mangan; B Zidar; R K Shadduck; Z Zeigler; A Winkelstein
Journal:  Am J Hematol       Date:  1985-08       Impact factor: 10.047

9.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Authors:  J U Gutterman; S Fine; J Quesada; S J Horning; J F Levine; R Alexanian; L Bernhardt; M Kramer; H Spiegel; W Colburn; P Trown; T Merigan; Z Dziewanowski
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

Review 10.  Clinical toxicity of interferons in cancer patients: a review.

Authors:  J R Quesada; M Talpaz; A Rios; R Kurzrock; J U Gutterman
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.